Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phadia AB

Division of Thermo Fisher Scientific Inc.
www.phadia.com

Latest From Phadia AB

Device/Diagnostics Quarterly Deal Statistics, Q1 2014

Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.

Medical Device Deals

Deals Shaping The Medical Industry, April 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.

BioPharmaceutical Medical Device

Medical Device Deals Update, March 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced February-March 2014.

Medical Device

Biopharma Dealmaking Quarterly Statistics, Q3 2012

Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Alias(es)
  • Pharmacia Diagnostics AB
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Magnus Lundberg, CEO
  • Contact Info
  • Phadia AB
    Phone: (46) 18 16 50 00
    P.O. Box 6460 Uppsala, SE-751 37
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register